Medicare Part B does not cover Wegovy. Part B pays for drugs a clinician administers to you in a medical setting, and Wegovy is self-administered, whether as the weekly injection or the once-daily tablet the FDA approved in December 2025.1KFF. A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People With Obesity Coverage for Wegovy runs through Medicare Part D in limited circumstances and, beginning July 1, 2026, through a new temporary program called the Medicare GLP-1 Bridge.
Why Part B Excludes Wegovy
Part B’s drug benefit is built around clinician-administered medications: infusions and injections given in a physician’s office, hospital outpatient department, or similar clinical setting. Because you give yourself Wegovy at home, it falls outside that category under every current indication, including the cardiovascular use the FDA approved in March 2024.1KFF. A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People With Obesity This isn’t a loophole or a formulary choice. It’s the structural line between Part B and Part D.
What Part B Does Pay For With Obesity
Part B does cover one obesity-related service, and it costs nothing if your provider accepts assignment. If your BMI is 30 or higher, Medicare pays for intensive behavioral therapy delivered in a primary care setting: weekly face-to-face sessions in the first month, biweekly sessions through month six, and monthly sessions through month twelve.2Medicare.gov. Obesity Behavioral Therapy The visits include a dietary assessment and counseling on diet and exercise.3CMS. Intensive Behavioral Therapy for Obesity To keep the monthly sessions in the second half of the year, you need to have lost at least 6.6 pounds in the first six months.4Medicare Interactive. Body Mass Index Screenings and Behavioral Counseling
When Part D Can Cover Wegovy
Medicare Part D plans are barred by statute from paying for drugs used for weight loss. But in March 2024 the FDA approved Wegovy for a separate purpose: reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who are also overweight or obese.5FDA. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults With Obesity or Overweight CMS confirmed Part D plans may cover Wegovy for that cardiovascular indication.1KFF. A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People With Obesity
Plans are not required to add it. Those that do typically require prior authorization, step therapy, or quantity limits.6Wellcare. Does Medicare Cover Weight Loss Drugs You will generally need a documented history of heart attack, stroke, or peripheral arterial disease, together with a diagnosis of obesity or overweight.1KFF. A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People With Obesity At a list price near $1,349 a month, specialty-tier coinsurance of 25 to 33 percent would be painful on its own, but the Inflation Reduction Act’s $2,000 annual out-of-pocket cap limits your total exposure.
The Medicare GLP-1 Bridge, Starting July 2026
On July 1, 2026, Medicare opens a separate pathway for Wegovy prescribed specifically for weight loss. The Medicare GLP-1 Bridge is a demonstration program administered by CMS through Humana as the central processor, operating outside the standard Part D benefit.7CMS. Medicare GLP-1 Bridge
What It Covers
The Bridge covers Wegovy (both the injection and the oral tablet), the Zepbound KwikPen (single-dose vials and pens are excluded), and Foundayo, the oral GLP-1 pill from Eli Lilly approved by the FDA on April 1, 2026.7CMS. Medicare GLP-1 Bridge8Novo Nordisk. FDA Approves Wegovy Pill9CNBC. Eli Lilly GLP-1 Pill Foundayo Approved for Obesity
Who Qualifies
You must be at least 18, enrolled in a Part D plan (either a standalone PDP or a Medicare Advantage plan with drug coverage), and not already receiving a GLP-1 through that plan. BMI and health conditions set the clinical thresholds:10Medicare.gov. Weight Loss Drugs
- BMI of 35 or higher: no additional condition needed.
- BMI of 30 to 34.99: plus heart failure with preserved ejection fraction, uncontrolled hypertension, chronic kidney disease stage 3a or higher, prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease.
- BMI of 27 to 29.99: plus prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease.
If you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, you are not eligible for the Bridge, because your standard Part D plan may already cover GLP-1 drugs for those diagnoses.7CMS. Medicare GLP-1 Bridge
What You Pay and How It Works
The copay is a flat $50 for a one-month supply at any dosage. Extra Help cannot reduce it, and the Medicare Prescription Payment Plan cannot spread it across months.10Medicare.gov. Weight Loss Drugs Because the Bridge sits outside Part D, your $50 does not count toward the Part D deductible or the $2,000 annual cap, and it will not appear on a Part D Explanation of Benefits.11NPR. Medicare Bridge GLP-1 Drugs Copay
Your provider prescribes the drug and submits a prior authorization to Humana, certifying that you are using it as part of a lifestyle program focused on diet and exercise. An approved authorization is valid through December 31, 2027, as long as you stay on the same medication.7CMS. Medicare GLP-1 Bridge
What Changes in 2027
Two things shift at the start of 2027, and both can affect what you pay for Wegovy.
First, the Bridge is a short-term program meant to hand off to a longer one called BALANCE, a voluntary CMMI demonstration that launches in January 2027 and runs through 2031.12KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid BALANCE is built into the Part D benefit, so plan sponsors have to opt in; CMS has said 80 percent participation is required for the model to proceed in 2027. Monthly cost-sharing would be capped at $50 for enhanced or employer plans and $125 for basic plans, with a $2,400 annual out-of-pocket maximum.13CMS. BALANCE Model If you are getting Wegovy through the Bridge and want to continue coverage in 2027, you may need to switch to a Part D plan that has joined BALANCE.
Second, semaglutide (the active ingredient in Wegovy and Ozempic) was selected for Medicare drug price negotiation under the Inflation Reduction Act. The negotiated Maximum Fair Price for Wegovy is $385.63 per month, effective January 1, 2027.14CMS. Selected Drugs and Negotiated Prices For people getting Wegovy through standard Part D for the cardiovascular indication, that price should lower cost-sharing in 2027.